CNBC Daily Open: Watching Iran’s economy; a losing game for bonds
Treasury Secretary Scott Bessent speaking to CNBC on May 14th, 2026 from Beijing, China. CNBC Hello, this is…
Foundayo: Eli Lilly wins U.K. approval, challenging Wegovy weight-loss pill
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Goldman is betting Nvidia will get a boost from health care as industry builds out AI capabilities
Nvidia will get a boost as companies in the health care and life sciences industries increase their push…
Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a…
Vertex kidney drug povetacicept succeeds in trial for IgAN
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters…